NCT06495086Completed
HFNC vs. NIV in Acute COPD Exacerbations
A High-Flow Nasal Cannula Versus Noninvasive Ventilation in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Single-blind Randomized Trial
Source: ClinicalTrials.gov · Last updated 10 Jul 2024
Brief summary (registry, in English)
The investigators investigated the efficacy and safety of High Flow Nasal Cannula (HFNC) at different flow rates compared to non-invasive ventilation (NIV) in patients presenting to the emergency department (ED) with acute exacerbations of Chronic obstructive pulmonary disease (COPD) who did not respond adequately to bronchodilator therapy and continued to exhibit hypercapnic respiratory failure. Specifically, the investigators tested the hypothesis that HFNC would be more effective at reducing partial pressure of carbon dioxide (PaCO2) levels and hospital stay duration and would be associated with greater patient comfort than NIV.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 137 (actual)
- First submitted
- 2 Jul 2024
- Start date
- 1 Sept 2023
- Primary completion date
- 1 Feb 2024
- Lead sponsor
- Haseki Training and Research Hospital
- Diseases
- COPD
- NCT number
- NCT06495086
What you commit to
- Study type: Interventional
- Participants enrolled: 137
- From 1 Sept 2023 to the primary completion date, 1 Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- patients showed persistent hypoxemia despite supplemental oxygen therapy;
Other illness
- patients had unstable cardiac arrhythmias or hemodynamic instability;
- patients had cardiogenic pulmonary edema, active hemoptysis, pneumothorax, recent upper respiratory tract/esophagus surgery, significant airway obstruction (e.g., laryngeal mass or tracheal tumor), active upper gastrointestinal bleeding, or facial trauma or deformities
Age
- patients aged younger than 18 years
Other
- patients had an arterial pH ≤ 7.25;
- patients were in cardiopulmonary arrest;
- patients were unconscious or uncooperative;
- patients could not protect their airway or manage secretions;
Who the study is looking for
- \- patients age ≥18 years with a confirmed diagnosis of COPD who presented to the ED with exacerbations that did not respond to bronchodilator therapy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Haseki Training and Research Hospital Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.